CN118221816A - LAG3 monoclonal antibody and application thereof - Google Patents
LAG3 monoclonal antibody and application thereof Download PDFInfo
- Publication number
- CN118221816A CN118221816A CN202410287305.9A CN202410287305A CN118221816A CN 118221816 A CN118221816 A CN 118221816A CN 202410287305 A CN202410287305 A CN 202410287305A CN 118221816 A CN118221816 A CN 118221816A
- Authority
- CN
- China
- Prior art keywords
- antibody
- chain variable
- variable region
- seq
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 title claims abstract description 44
- 102000017578 LAG3 Human genes 0.000 title claims abstract description 42
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims abstract description 8
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 4
- 239000012634 fragment Substances 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 29
- 229940127121 immunoconjugate Drugs 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 11
- 239000012636 effector Substances 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101150036449 SIRPA gene Proteins 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108090001008 Avidin Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 102100036352 Protein disulfide-isomerase Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000002331 protein detection Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 230000000903 blocking effect Effects 0.000 abstract description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 6
- 239000003446 ligand Substances 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000005909 tumor killing Effects 0.000 abstract 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 35
- 150000001413 amino acids Chemical group 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000011161 development Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102100038664 Fibrinogen-like protein 1 Human genes 0.000 description 6
- 101001031635 Homo sapiens Fibrinogen-like protein 1 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 5
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- -1 etc.) Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 101100510618 Homo sapiens LAG3 gene Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- 102000043279 ADAM17 Human genes 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100028666 C-type lectin domain family 4 member G Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 101001136701 Dictyostelium discoideum Prespore-specific protein E Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 102000000802 Galectin 3 Human genes 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100032530 Glypican-3 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000766915 Homo sapiens C-type lectin domain family 4 member G Proteins 0.000 description 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000005091 electrochemiluminescent agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229940121484 relatlimab Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention provides a plurality of monoclonal antibodies capable of recognizing lymphocyte activating gene 3 (LAG 3) with high affinity. The antibodies have high affinity and are capable of blocking the binding of LAG3 protein to its ligand MHC-II or FGL 1. The neutralizing monoclonal antibody provided by the invention not only has good in-vitro blocking activity, but also has very strong thermal stability, and can promote proliferation of PBMC cells and release of cytokines in vitro, and enhance tumor killing activity of bispecific antibodies and CAR-T.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a high-affinity monoclonal antibody for recognizing LAG3 and application thereof.
Background
Lymphocyte activating gene 3 (LAG 3, CD 223) is a member of the immunoglobulin superfamily and is an important negative regulator of T cell surface. LAG3 was found in 1990 on activated NK cells and T cells, and it contains 4 extracellular IgSF domains and 1 transmembrane domain and 1 intracellular domain, which can be cleaved into secreted sLAG3 by proteases ADAM10 and ADAM17 between the D4 domain and transmembrane domain. In addition, LAG3 was detected on DC cells, B cells, tumor infiltrating lymphocytes, NK cells, regulatory T cells, depleted cd8+ T cells, and the like.
LAG3 has about 20% homology with MHC-II in the gene structure, and LAG3 has higher affinity with MHC-II than CD4 protein. However, unlike CD4, CD4 is mainly expressed on the cell surface, whereas LAG3 is largely intracellular and LAG3 rapidly migrates to the cell surface to function upon antigen stimulation. Upregulation of expression of LAG3 molecules on the T-cell surface has led to downregulation of T-cell proliferation, and since LAG3 has a higher affinity for MHC-II molecules than CD4, while blocking LAG3 interaction with MHC-II by antibodies can significantly enhance T-cell activity, LAG3 has in the past been widely recognized as downregulating T-cell activity by interaction with MHC-II molecules. However, in recent years, it has been found that antibodies against LAG3 which do not block binding to MHC-II still have some antitumor activity, and thus LAG3 may have other ligands to function, including Galectin-3, LSECtin, FGL1, etc. One article on Cell 2019 shows that the primary inhibitory ligand (Fibrinogen-like Protein 1Is a Major Immune Inhibitory Ligand of LAG3,Wang J,et al,Cell,2019;176:334-347). of LAG3, which FGL1 may also be, is a new strategy in tumor immunotherapy by preparing antibodies to block LAG3-MHC-II or LAG3-FGL1 interactions.
Disclosure of Invention
The present invention aims to provide monoclonal antibodies that recognize LAG3 with high affinity. Antibodies provided include immunoconjugates of antibody fragments (e.g., single chain variable region fragments (scFv)) and effector molecules (e.g., toxin proteins). Also provided are compositions comprising antibodies that specifically bind LAG3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acid molecules, and isolated host cells expressing the nucleic acid molecules.
The specific technical scheme of the invention is as follows:
A monoclonal antibody or antigen-binding fragment thereof of lymphocyte activation gene 3 comprising a heavy chain variable region and a light chain variable region, said monoclonal antibody or antigen-binding fragment thereof comprising the amino acid sequence of SEQ ID NO:1, a heavy chain variable region CDR1, SEQ ID NO:2, a heavy chain variable region CDR2, SEQ ID NO:3, a heavy chain variable region CDR3 as set forth in SEQ ID NO:4, the light chain variable region CDR1, SEQ ID NO:5, the light chain variable region CDR2, SEQ ID NO:6, and a light chain variable region CDR3.
There are three known subtypes of human LAG3 (subtypes 1-3). The nucleic acid and amino acid sequences of three subtypes of LAG3 are known, including GenBank accession numbers: NM_002286.6 and NP_002277.4 (subtype 1); NM_001414176.1 and NP_001401105.1 (subtype 2); NM-001414177.14 and NP-001401106.1 (subtype 3). The antibodies of the invention may bind to one or more of the three human LAG3 subtypes, or conservative variants thereof.
Specifically, the LAG3 antibody or antigen-binding fragment thereof of the present invention is:
(1) The amino acid sequence of the heavy chain variable region of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 7, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 8;
Or (2) the heavy chain variable region amino acid sequence of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 9, and the light chain variable region amino acid sequence is shown as SEQ ID NO. 10.
Or (3) the amino acid sequence of the heavy chain variable region of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 11, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 12.
Or (4) the heavy chain variable region amino acid sequence of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 13, and the light chain variable region amino acid sequence is shown as SEQ ID NO. 14.
Or (5) the heavy chain variable region amino acid sequence of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 15, and the light chain variable region amino acid sequence is shown as SEQ ID NO. 16.
The antibodies of the invention are single chain antibodies, diabodies, monoclonal antibodies or chimeric antibodies.
The monoclonal antibodies of the invention may be of any isotype. May be, for example, igM or IgG antibodies, such as IgG1 or IgG2. The types of antibodies that can specifically bind LAG3 can be converted to each other according to known methods (e.g., igG can be converted to IgM). Class conversion may also be used to convert one subclass of IgG to another, e.g., from IgG1 to IgG2.
The antibodies of the invention may be:
(1) Fab, fragments comprising monovalent antigen binding fragments of an antibody molecule, which can be produced by digesting an intact antibody with papain to produce an intact light chain and a portion of one heavy chain;
(2) Fab', antibody molecule fragments obtainable by treating an intact antibody with pepsin followed by reduction to yield a portion of intact light and heavy chains; two Fab' fragments are obtained per antibody molecule;
(3) (Fab') 2, an antibody fragment obtainable by treating an intact antibody with pepsin, but without subsequent reduction; f (ab ') 2 is a dimer of two Fab' fragments linked together by two disulfide bonds;
(4) Fv, gene Cheng Pianduan containing the light chain variable region and heavy chain variable region expressed as 2 chains;
(5) A single chain antibody (e.g., scFv), a genetically engineered molecule comprising a light chain variable region and a heavy chain variable region linked by a suitable polypeptide linker to form a genetically fused single chain molecule;
(6) A dimer of single chain antibodies (scFv 2), defined as a dimer of scFv (also known as a "minibody");
(7) VH single domain antibodies, antibody fragments consisting of heavy chain variable regions.
Those skilled in the art will appreciate that conservative variants of an antibody may be made. Amino acid substitutions (e.g., 1,2, 3, 4, or 5 amino acid substitutions) may be made in the VH and/or VL regions, with the substituted VH and VL still retaining the ability to bind LAG3, or having greater binding ability to LAG 3. Conservative substitutions of functionally similar amino acids are well known to those of ordinary skill in the art. The following six groups are examples of amino acids that are considered to be conservative substitutions for one another:
1) Alanine (a), serine (S), threonine (T);
2) Aspartic acid (D), glutamic acid (E);
3) Asparagine (N), glutamine (Q);
4) Arginine (R), lysine (K);
5) Isoleucine (I), leucine (L), methionine (M), valine (V);
6) Phenylalanine (F), tyrosine (Y), tryptophan (W).
It is another object of the present invention to provide a recombinant protein comprising the antibody or antigen-binding fragment thereof of the present invention and a tag sequence that facilitates expression and/or purification. The tag sequence includes but is not limited to a 6x His tag.
The invention also aims to disclose the application of the monoclonal antibody or antigen binding fragment, the bispecific antibody or fusion protein, the immunoconjugate and the nucleic acid molecule in the preparation of immune checkpoint inhibitors. The immune checkpoint inhibitor is an agent for diagnosing or treating autoimmune diseases, chronic reinfection or tumors. The tumor is non-Hodgkin's lymphoma, chronic lymphocytic leukemia, hodgkin's disease, solid tumor or metastasis.
The detectable label of the present invention is a substance that can be detected by an isotope analyzer, an enzyme-labeled instrument, a bioluminescence detector, a chemiluminescent detector, an electrochemiluminescence detector, a fluorescence analyzer, or a naked eye visualization, including, but not limited to, radioisotopes (e.g., 3H、14C、15N、35S、90Y、、99Tc、111In、125I、131I)、 enzymes useful for detection (e.g., horseradish peroxidase, beta-galactosidase, alkaline phosphatase, glucose oxidase, etc.), fluorescent proteins (e.g., green Fluorescent Protein (GFP), yellow Fluorescent Protein (YFP), allophycocyanin APC, phycoerythrin PE), bioluminescent labels (e.g., luciferase), fluorescent compounds (e.g., fluorescein isothiocyanate, rhodamine, 5-dimethylamino-1-naphthalenesulfonyl chloride, phycoerythrin, fluorescent dye Cy3, cy5, rare earth phosphors, quantum dots, etc.), biotin, magnetic agents (e.g., gadolinium), electrochemiluminescent agents (e.g., ruthenium terpyridyl), colloidal gold.
The effector molecule may be linked to the antibodies of the invention using any means known to those skilled in the art. For example, the antibody may be functionally linked (by chemical coupling, gene fusion, non-covalent association, or otherwise) to one or more other molecular entities. The method of linking the effector molecule to the antibody varies depending on the chemical structure of the effector molecule. Polypeptides generally contain multiple functional groups; such as carboxylic acid (COOH), free amino (-NH 2) or thiol (-SH), which can be used to react with suitable functional groups on antibodies to bind to the effector molecule. Alternatively, the antibody may be derivatized to expose or attach additional reactive functional groups. The derivatization may include attachment of any of a variety of known linker molecules. The linker may be any molecule for binding the antibody to an effector molecule. The linker is capable of forming a covalent bond with the antibody and effector molecule. Suitable linkers are well known to those skilled in the art and include, but are not limited to, straight or branched chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. Where the antibodies and effector molecules are polypeptides, the linker may be attached to the constituent amino acids or to the alpha carbon amino and carboxyl groups of the terminal amino acids through its side groups (e.g., through disulfide bonds of cysteines). Typically, the antibody or portion thereof is derivatized such that binding to the target antigen is not adversely affected by the derivatization or labeling.
In some cases, it is desirable to release the effector molecule from the antibody when the immunoconjugate has reached its target site. Thus, in these cases, the immunoconjugate will comprise a cleavable bond near the target site. Cleavage of the linker to release the effector molecule from the antibody may be caused by enzymatic activity or by conditions under which the immunoconjugate is located within the target cell or near the target site.
It is another object of the present invention to provide a polynucleotide encoding an antibody, recombinant protein or immunoconjugate according to the invention.
Another object of the present invention is to provide a vector comprising the polynucleotide of the present invention. The carrier comprises: bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors.
It is another object of the present invention to provide a pharmaceutical composition comprising one or more of the antibodies or antigen binding fragments thereof, recombinant proteins, bispecific antibodies, immunoconjugates, polynucleotides, vectors, or genetically engineered host cells of the invention. The pharmaceutical composition further comprises a pharmaceutically acceptable carrier. The antibody, recombinant protein, bispecific antibody, immunoconjugate, polynucleotide, vector or genetically engineered host cell is soluble in an aqueous carrier, such as buffered saline or the like. Pharmaceutically acceptable excipients required to approximate physiological conditions, such as pH adjusting and buffering agents, sodium acetate, sodium chloride, potassium chloride, calcium chloride or sodium lactate, and the like, may also be included.
The medicament or the pharmaceutical composition can form a pharmaceutical composition with one or more of GITR, CD137, PD-1, PD-Ll, OX40, CTLA4, TIGIT, LAG3, CD47, SIRPa immune checkpoint inhibitor. The medicament or the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, excipient and/or diluent.
It is a further object of the present invention to provide the use of an antibody or antigen binding fragment thereof, recombinant protein, immunoconjugate, polynucleotide, vector or genetically engineered host cell according to the invention for the preparation of a therapeutic or diagnostic agent for autoimmune diseases, viral infections or cancer.
The cancer is liver cancer, gastric cancer, colorectal cancer, lung cancer, ovarian cancer, or any other type of cancer that expresses LAG 3.
The monoclonal antibodies or antigen binding fragments thereof disclosed herein may also be used to prepare chimeric antigen receptors (CARs; also known as chimeric T cell receptors, artificial T cell receptors or chimeric immune receptors) or bispecific antibodies.
The pharmaceutical or neutraceutical compositions of the invention may also include activated or non-activated T cells, genetically modified T cells, human lymphocytes induced, activated and cultured in vitro.
The invention also provides a detection reagent, a diagnostic reagent or a diagnostic kit which comprises one or more of the antibody or antigen binding fragment, the bispecific antibody or fusion protein, the immunoconjugate, the nucleic acid molecule or the carrier, and is used for detecting whether LAG3 protein exists in a biological sample and/or detecting the content of the LAG3 protein.
In specific embodiments of the invention, high affinity LAG3 monoclonal antibodies are disclosed. The invention also discloses the in vitro activity of the antibody and the effect of treating liver cancer by combining hYP7-OKT3 bispecific antibody (anti-tumor activity research of T cell type bispecific antibody in liver cancer and small cell lung cancer, chen Xin, 2020, doctor's laboratory paper of Huazhong university). The antibodies and compositions can be used to treat tumors that are positive for LAG3 expression.
The antibodies and compositions provided herein can be used for a variety of purposes, such as for molecular diagnosis of tumors. The sample may be any sample including, but not limited to, tissue from biopsies, autopsies and pathological specimens. Biological samples also include sections of tissue, such as frozen sections taken for histological purposes. Biological samples also include body fluids such as blood, serum, plasma, sputum, spinal fluid or urine. Biological samples are typically obtained from mammals, including humans, non-human primates, mice, and the like.
The invention has the advantages that:
the monoclonal antibody provided by the invention has high affinity (Kd values are in nM and pM levels and even higher), and has good thermal stability. The monoclonal antibody provided by the invention can block the interaction of LAG3 and ligand MHC-II or FGL1 thereof with high activity. The monoclonal antibody provided by the invention can obviously enhance the anti-tumor activity of the single drug by being combined with the bispecific antibody or the PD1 antibody.
Drawings
FIG. 1 shows the affinity assay of the LAG3 monoclonal antibody M234 scFv-HF and LAG3ECD-hFc according to the present invention.
FIG. 2 shows the affinity assay of the LAG3 monoclonal antibody M234 scFv-HF and LAG3D1D2-hFc according to the present invention.
FIG. 3 shows the affinity assay of M234 IgG for Bio-LAG3D1D 2-hFc.
FIG. 4 shows M234 IgG binding activated PBMC cells according to the invention.
FIG. 5 affinity of Bio-LAG3D1D2-hFc with FGL 1-hFc.
FIG. 6 shows the ability of M234 IgG to block BioLAG D1D2-hFc binding to FGL 1-hFc.
FIG. 7M 234 IgG blocks BioLAG interaction of 3D1D2-hFc with Raji cell surface MHC-II.
FIG. 8M 234 IgG inhibits growth of Huh-7 tumor cells in NOD-SCID mice.
Figure 9 weight change after treatment of Huh7 tumor bearing mice with m234 IgG.
FIG. 10 affinity detection of humanized M234 monoclonal antibodies.
Detailed Description
The present disclosure describes the preparation and identification of monoclonal antibodies that bind LAG 3. Particular embodiments disclose the isolation and characterization of LAG 3-targeting monoclonal antibodies.
The invention will now be described in further detail with reference to the following specific examples, which are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. The terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art unless otherwise indicated. In the following examples, various processes and methods, which are not described in detail, are conventional methods well known in the art.
Abbreviations (abbreviations)
CDR complementarity determining region
CTL cytotoxic T lymphocytes
ELISA enzyme-linked immunosorbent assay
FACS fluorescence activated cell sorting
GPC3 glypican 3
BLI biological film interference technique
HCC hepatocellular carcinoma
HFc human Fc
Ig immunoglobulin
MAb monoclonal antibodies
PE phycoerythrin
EXAMPLE 1 preparation of monoclonal antibodies to LAG3 according to the invention
This example describes the preparation of high affinity monoclonal antibodies against tumor-associated LAG 3.
The truncated protein of LAG3ECD and LAG3D1D2 fusion hffc was expressed and purified using 293F cells (see np_002277.4 for truncation information). Mice were immunized with LAG3ECD-hFc and LAG3D1D2-hFc proteins at 6 weeks of age, 50 μg each time, 3 weeks apart, the spleens of the mice were harvested 2 times after immunization, total RNA in the spleens was extracted, reverse transcribed into cDNA as a template for the establishment of phage antibody libraries, and mouse antibody phage libraries (inventory capacity 4.6x10 9) were constructed. After 3 times of panning on phage library, single clones were randomly picked for sequencing using LAG3ECD-hFc protein as antigen, obtaining high affinity LAG3 monoclonal antibody M234.
The amino acid sequences of the complementarity determining regions (CDR regions) and the variable regions of antibody M234 are shown in tables 1 and 2:
TABLE 1 CDR amino acid sequences of LAG 3M 234 monoclonal antibodies (according to Kabat and IMGT)
TABLE 2 amino acid sequence of variable region of LAG3M234 monoclonal antibody
EXAMPLE 2 affinity of monoclonal antibody M234 scFv-HF of LAG3 to LAG3 protein according to the present invention
The monoclonal antibody scFv-HF of example 1 was prokaryotic expressed using HB2151, and the expression product was purified using Ni-NTA chromatography column (GE HEALTHCARE). The antibody affinity was detected by ELISA.
First, LAG3ECD-hFc protein or LAG3D1D2-hFc protein is respectively coated on the bottom of ELISA plate, then M234 scFv-HF prepared above is respectively added, the first hole is 200nM, gradient dilution is carried out at 1:3, incubation is carried out, and goat anti-FLAG antibody marked by HRP is used as secondary antibody for detection. And detecting absorbance by using a multifunctional enzyme-labeled instrument after color development by using TMB color development liquid, and finally analyzing the result by using GRAPHPAD PRISM. As shown in FIGS. 1 and 2, M234 had affinities of 0.2nM and 0.14nM for LAG3ECD-hFc and LAG3D1D2-hFc, respectively.
Example 3 affinity of M234 IgG for LAG3 protein according to the present invention
The heavy chain variable region of the antibody M234 obtained in example 1 was connected to the heavy chain constant region of an IgG1 type antibody, and after the light chain variable region was connected to the light chain constant region, it was constructed on IgG expression vectors each having two promoters, and expression was performed using 293F cells, and the expression product was purified using a ProteinA column (GE HEALTHCARE). The antibody affinity was detected by ELISA.
Firstly, M234 IgG proteins are respectively coated on the bottom of an ELISA plate, and meanwhile, NHS-Biotin (biological organism) ice is used for marking LAG3D1D2-hFc proteins, so that Biotin marked Bio-LAG3D1D2 is obtained. The biotin-labeled BioLAG D1D2-hFc was then diluted in a first well 200nM 1:3 gradient, incubated therewith, and detected using HRP-labeled streptavidin as a secondary antibody. And detecting absorbance by using a multifunctional enzyme-labeled instrument after color development by using TMB color development liquid, and finally analyzing the result by using GRAPHPAD PRISM. The results are shown in FIG. 3, bioLAG D1D2-hFc had an affinity of 0.45nM for the M234 monoclonal antibody.
EXAMPLE 4 detection of M234 IgG stability
The Tm value is a parameter quantitatively describing the thermal stability of a protein, and is one of the most commonly used indexes in the evaluation of patent drug properties. The higher the Tm value means the more stable the protein conformation. Stability of the antibody prepared in example 1 was determined using Prometheus NT.48 from Nano Temper: the antibody concentration was diluted to 500. Mu.g/ml, then loaded and raised from 25℃to 95℃at a rate of 1℃per minute. Finally, the T m value of the antibody is obtained. As a result, as shown in Table 3, the antibody M234 had T m of 61.67 ℃and T m of 87.73 ℃and an aggregation temperature of 89.12℃and M234 had higher thermostability and aggregation than the LAG3 monoclonal antibody Relatlimab which was already on the market.
TABLE 3T m values for monoclonal antibodies of the invention
EXAMPLE 4FACS detection of binding of M234 IgG to LAG 3-positive cell lines according to the invention
PBMC cells were incubated with CD3Ab/CD28Ab and IL-2 followed by addition of 10% fetal bovine serum (Hyclone, logan, UT), 1% L-glutamine and 1% penicillin-streptomycin (Invitrogen, carlsbad, calif.) using 1640 medium (Invitrogen, carlsbad, calif.). After harvesting the cells, the antibodies prepared in example 3 were combined with activated PBMC cells, PE-labeled goat anti-human Fc secondary antibody was added, and the antibodies bound to the cell surface were detected. The results are shown in FIG. 4, and the M234 prepared in example 3 has an affinity of 0.10nM for PBMC cells.
EXAMPLE 5M 234 IgG blocking binding of LAG3 to FGL1 according to the invention
FGL1 was first coated on ELISA plate bottom, while using NHS-Biotin (Bio) ice to label LAG3D1D2-hFc protein to obtain Biotin-labeled Bio-LAG3D1D2.Bio-LAG3D1D2 at 1:2 was diluted from 1000nM, incubated at 37℃for 30min after addition to the ELISA plate bottom, and detected using HRP-labeled streptavidin as secondary antibody. And detecting absorbance by using a multifunctional enzyme-labeled instrument after color development by using TMB color development liquid, and finally analyzing the result by using GRAPHPAD PRISM. The results show that LAG3-FGL1 affinity is shown in FIG. 5.
Antibody blocking experiments FGL1 was first coated onto the bottom of ELISA plates, then subjected to first well 200nm 1:3 gradient dilution, and M234 IgG prepared in example 3 was incubated with 100nM BioLAG3D1D2 min separately and then added to ELISA plates, and HRP-labeled streptavidin was used as secondary antibody for detection. And detecting absorbance by using a multifunctional enzyme-labeled instrument after color development by using TMB color development liquid, and finally analyzing the result by using GRAPHPAD PRISM. The antibody blocking activity is shown in FIG. 6, which shows that antibody M234 has LAG3-FGL1 blocking activity with IC 50 of 15nM.
EXAMPLE 6M 234 IgG blocking binding of LAG3 to MHC-II according to the invention
Raji cells naturally express MHC-II at a high level, and Raji cells are used for blocking experiments. Raji cells were cultured using 1640 medium (Invitrogen, carlsbad, calif.) with 10% fetal bovine serum (Hyclone, logan, UT), 1% L-glutamine, and 1% penicillin-streptomycin (Invitrogen, carlsbad, calif.). 10. Mu.g/ml LAG3ECD-hFc protein was incubated with gradient diluted antibody M234 IgG prepared in example 3 for 30min, then added to the collected Raji cells and incubated on ice for 30min. Finally, PE-labeled goat anti-human secondary antibodies are added, and antibodies bound to the cell surface are detected. As a result, as shown in FIG. 7, antibody M234 had LAG3-MHC-II blocking activity with blocking IC 50 of 6.2nM.
EXAMPLE 7M234 IgG inhibits tumor growth in mice
The liver cancer cell line Huh-7 is selected as a test cell for the tumor-inhibiting activity of the antibody. Huh-7 cells were cultured using DMEM medium (Invitrogen, carlsbad, calif.) with 10% fetal bovine serum (Hyclone, logan, UT), 1% L-glutamine and 1% penicillin-streptomycin (Invitrogen, carlsbad, calif.). After cell digestion, each mouse was injected with 5X 10 6 cells, after tumor formation, each mouse was injected with 5X 10 6 PBMC cells, and immunotherapy was performed with 0.2mg/kg hYP7-OKT3 bispecific antibody (antibody preparation procedure was referred to the doctor's thesis of Chen Xin, anti-tumor activity study of T cell type bispecific antibody in liver cancer and small cell lung cancer, university of Huazhong agriculture, 2020)) in combination with 10mg/kg of LAG3 monoclonal antibody prepared in example 3. The tumor growth curves of the mice are shown in fig. 8 and table 4, and the weight changes are shown in fig. 9. The results show that the M234 IgG monoclonal antibody combined with the bispecific antibody can remarkably enhance the anti-tumor activity.
Table 4 mouse tumor volume
Example 8 humanized M234 and affinity detection of humanized M234 IgG
Humanized transformation is carried out on the monoclonal antibody M234 by using a skeleton replacement method of a human antibody Germline to obtain a humanized Hu1M234 sequence, a heavy chain of the humanized M234 is subjected to back mutation to obtain Hu2M234, a light chain of the humanized M234 is subjected to back mutation to obtain Hu3M234, the light chain and the heavy chain are subjected to back mutation simultaneously to obtain Hu4M234, and the humanized sequence is shown in a table 5.
The heavy chain variable region of humanized M234 was linked to the heavy chain constant region of a human IgG1 type antibody and a Flag tag was added after the Fc region, and the light chain variable region of humanized M234 was linked to the kappa light chain constant region of a human antibody, and then cloned into IgG expression vectors, respectively, to construct IgG expression plasmids, and expression was performed using 293F cells, and the expression product was purified using a ProteinA column (GE HEALTHCARE). The affinity of HuM234 IgG was detected by ELISA.
TABLE 5 VH and VL sequences of humanized M234
Coating LAG3ECD-hFc protein on the bottom of an ELISA plate, adding humanized M234 IgG-Flag antibody, diluting the first well by 200nM, incubating the rest of the wells according to a 1:3 gradient, detecting by using HRP-labeled FLAG antibody, detecting absorbance by using a multifunctional enzyme-labeled instrument after color development by using TMB color development liquid, and finally analyzing the experimental result by using GRAPHPAD PRISM. The results are shown in FIG. 10, where humanized HuM234 IgG affinities were 0.96nM,0.52nM,0.59nM,0.16nM, respectively, and where Hu4M234 affinities were substantially identical to the original M234 antibody affinities.
Claims (17)
1. A monoclonal antibody or antigen binding fragment thereof that targets human lymphocyte activation gene 3, comprising a heavy chain variable region and a light chain variable region, characterized in that:
The monoclonal antibody or antigen binding fragment thereof comprises SEQ ID NO:1, a heavy chain variable region CDR1, SEQ ID NO:2, a heavy chain variable region CDR2, SEQ ID NO:3, a heavy chain variable region CDR3 as set forth in SEQ ID NO:4, the light chain variable region CDR1, SEQ ID NO:5, the light chain variable region CDR2, SEQ ID NO:6, and a light chain variable region CDR3.
2. The monoclonal antibody or antigen-binding fragment thereof according to claim 1, wherein:
(1) The amino acid sequence of the heavy chain variable region of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 7, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 8;
Or (2) the heavy chain variable region amino acid sequence of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 9, and the light chain variable region amino acid sequence is shown as SEQ ID NO. 10.
Or (3) the amino acid sequence of the heavy chain variable region of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 11, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 12.
Or (4) the heavy chain variable region amino acid sequence of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 13, and the light chain variable region amino acid sequence is shown as SEQ ID NO. 14.
Or (5) the heavy chain variable region amino acid sequence of the antibody or antigen binding fragment thereof is shown as SEQ ID NO. 15, and the light chain variable region amino acid sequence is shown as SEQ ID NO. 16.
3. The monoclonal antibody or antigen-binding fragment thereof according to claim 1, characterized in that the antibody is a single chain antibody, a diabody, a chimeric antibody or a humanized antibody.
4. The monoclonal antibody or antigen-binding fragment thereof according to claim 1, characterized in that the antibody is a VH single domain antibody, a Fab fragment, a Fab 'fragment, a F (ab)' 2 fragment, a single chain variable fragment scFv or a disulfide stabilized variable fragment dsFv.
5. A recombinant protein comprising the monoclonal antibody or antigen-binding fragment thereof of any one of claims 1-4 and a tag sequence that facilitates expression and/or purification.
6. Bispecific antibody or fusion protein characterized in that it comprises a monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1-4 or a recombinant protein according to claim 5.
7. Immunoconjugates characterized in that they contain the monoclonal antibodies or antigen-binding fragments thereof according to any one of claims 1 to 4, the recombinant proteins according to claim 5 or the bispecific antibodies or fusion proteins according to claim 6.
8. The immunoconjugate of claim 7, wherein the effector molecule of the immunoconjugate is selected from one or more of a fluorescent-tagged radiolabel, avidin, biotin, an enzyme, a toxin, or a chemotherapeutic agent.
9. A polynucleotide encoding an antibody or antigen-binding fragment thereof according to any one of claims 1-4, or a recombinant protein according to claim 5, or a bispecific antibody or fusion protein according to claim 6, or an immunoconjugate according to claim 7 or 8.
10. A vector comprising the polynucleotide of claim 9.
11. Use of the monoclonal antibody or antigen binding fragment thereof of any one of claims 1-4, the recombinant protein of claim 5, the bispecific antibody or fusion protein of claim 6, the immunoconjugate of claim 7 or 8, the polynucleotide of claim 9, or the vector of claim 10 for the preparation of an immune checkpoint inhibitor.
12. Use according to claim 11, characterized in that the immune checkpoint inhibitor is an agent or drug for diagnosing or treating an immune disease, chronic viral infection or tumor.
13. A pharmaceutical composition comprising one or more of the monoclonal antibodies or antigen binding fragments thereof of claims 1-4, the recombinant protein of claim 5, the bispecific antibody or fusion protein of claim 6, the immunoconjugate of claim 7 or 8, the polynucleotide of claim 9, or the vector of claim 10.
14. The pharmaceutical composition of claim 13, further comprising one or more of GITR, CD137, PD-1, PD-L1, OX40, CTLA4, TI GIT, LAG3, CD47, SIRPa immune checkpoint inhibitor.
15. The pharmaceutical composition according to claim 13, characterized in that the pharmaceutical composition further comprises one or more of activated or non-activated T cells, genetically modified T cells or human lymphocytes induced, activated and cultured in vitro.
16. A host cell, characterized in that it carries a polynucleotide according to claim 9 or a vector according to claim 10.
Lag-3 protein detection reagent, diagnostic reagent or diagnostic kit, characterized in that it comprises one or several of the monoclonal antibodies or antigen-binding fragments thereof according to claims 1-4, the bispecific antibodies and fusion proteins according to claims 5 or 6, the immunoconjugates according to claims 7 or 8, the nucleic acid molecules according to claim 9 or the vectors according to claim 10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410287305.9A CN118221816A (en) | 2024-03-13 | 2024-03-13 | LAG3 monoclonal antibody and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410287305.9A CN118221816A (en) | 2024-03-13 | 2024-03-13 | LAG3 monoclonal antibody and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118221816A true CN118221816A (en) | 2024-06-21 |
Family
ID=91503290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410287305.9A Pending CN118221816A (en) | 2024-03-13 | 2024-03-13 | LAG3 monoclonal antibody and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118221816A (en) |
-
2024
- 2024-03-13 CN CN202410287305.9A patent/CN118221816A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105579471B (en) | Antibodies that bind human programmed death ligand 1(PD-L1) | |
JP5941615B2 (en) | Method for immunological measurement of human CXCL1 protein | |
CN109988240B (en) | anti-GPC-3 antibodies and uses thereof | |
CN110382533B (en) | Antibodies that specifically bind CD66c and uses thereof | |
CN101245101B (en) | Antihuman CD146 monoclone antibody, composition containing the same, and method for testing dissolubility CD146 | |
US9738726B2 (en) | HER2-specific monoclonal antibodies and conjugates thereof | |
CN114539411B (en) | ROR1 antibody or antigen binding fragment thereof | |
CN112094348B (en) | Anti-human Tim3 antibody or functional fragment thereof and application thereof | |
JP2022516848A (en) | BTN3A binding protein and its use | |
CN113637077B (en) | Antibody for resisting MICA and application thereof | |
WO2021121373A1 (en) | Anti-human programmed death -1 (pd-1) monoclonal antibody | |
CN115667304A (en) | Anti-human LAG-3 antibodies and their use in Immunohistochemistry (IHC) | |
WO2023219147A1 (en) | Novel anti-ccr8 antibodies for detecting ccr8 | |
CN109810194B (en) | anti-DR 5 antibody and preparation method and application thereof | |
CN114671953B (en) | Single domain anti-Nectin-4 antibodies | |
CN117586397A (en) | Anti-human CD147 monoclonal antibody, expression vector, cell strain and application thereof | |
CN113880948B (en) | anti-CA 724 antibody or antigen-binding fragment thereof, and preparation method and application thereof | |
KR20120134547A (en) | A marker comprising anti-atic autoantibodies and a composition comprising antigen thereof for diagnosing liver cancer | |
CN118221816A (en) | LAG3 monoclonal antibody and application thereof | |
CN110615841B (en) | Anti-human CD47 monoclonal antibody and application thereof | |
CN115843256A (en) | anti-ERBB 3 antibody or antigen binding fragment thereof and medical application thereof | |
CN110938146A (en) | TIM-3 single domain antibody and application thereof | |
CN116836291B (en) | Anti-idiotype antibody of anti-CD 47-CLDN18.2 bispecific antibody, preparation method and application thereof | |
CN116063536B (en) | Anti-human MxA monoclonal antibody, preparation method and application thereof | |
RU2493166C1 (en) | Nanoantibody specifically binding cea protein, method of its usage for detection of this protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |